About atea pharmaceuticals inc - AVIR
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
AVIR At a Glance
Atea Pharmaceuticals, Inc.
225 Franklin Street
Boston, Massachusetts 02110
| Phone | 1-857-284-8891 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -168,385,000.00 | |
| Sector | Health Technology | Employees | 56 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AVIR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.645 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.887 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.01 |
AVIR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,006,875.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AVIR Liquidity
| Current Ratio | 24.854 |
| Quick Ratio | 24.854 |
| Cash Ratio | 24.443 |
AVIR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.782 |
| Return on Equity | -33.878 |
| Return on Total Capital | -38.225 |
| Return on Invested Capital | -33.794 |
AVIR Capital Structure
| Total Debt to Total Equity | 0.374 |
| Total Debt to Total Capital | 0.373 |
| Total Debt to Total Assets | 0.353 |
| Long-Term Debt to Equity | 0.192 |
| Long-Term Debt to Total Capital | 0.191 |
Atea Pharmaceuticals Inc in the News
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.